Esophageal motility disorders: Medical therapy

Journal of Clinical Gastroenterology

Volumn 42, Issue 5, 2008, Pages 652-658

  Lacy, Brian E ^a   Weiser, Kirsten ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Achalasia; Diffuse esophageal spasm; Esophageal manometry; Esophageal motility; Esophagus; Ineffective esophageal motility; Nutcracker esophagus; Treatment

Indexed keywords

ANTIDEPRESSANT AGENT; BETHANECHOL; BOTULINUM TOXIN; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; GLYCERYL TRINITRATE; IMIPRAMINE; ISOSORBIDE DINITRATE; NIFEDIPINE; NITRATE; PEPPERMINT OIL; PHOSPHODIESTERASE V INHIBITOR; PROTON PUMP INHIBITOR; SERTRALINE; SILDENAFIL; SPASMOLYTIC AGENT; TADALAFIL; TEGASEROD; THEOPHYLLINE; TRAZADONE; UNCLASSIFIED DRUG; VARDANAFIL;

CLINICAL TRIAL; CONFERENCE PAPER; DIAGNOSTIC PROCEDURE; ECONOMIC ASPECT; ESOPHAGUS ACHALASIA; ESOPHAGUS DISEASE; ESOPHAGUS FUNCTION DISORDER; ESOPHAGUS MOTILITY; ESOPHAGUS PAIN; EVIDENCE BASED MEDICINE; HEARTBURN; HUMAN; LOWER ESOPHAGUS SPHINCTER; MANOMETRY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SINGLE DRUG DOSE;

CALCIUM CHANNEL BLOCKERS; DIGESTIVE SYSTEM SURGICAL PROCEDURES; ESOPHAGEAL MOTILITY DISORDERS; GASTROINTESTINAL MOTILITY; HUMANS; MUSCLE CONTRACTION; NEUROMUSCULAR AGENTS; PHOSPHODIESTERASE INHIBITORS; TREATMENT OUTCOME;

EID: 42449109182     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31815bd223     Document Type: Conference Paper

References (64)

1. Sonnenberg A, Massey BT, McCarty DJ, et al. Epidemiology of hospitalization for achalasia in the United States. Dig Dis Sci. 1993;38:233-244.
2. Mayberry JF, Rhodes J. Achalasia in the city of Cardiff from 1926 to 1977. Digestion. 1980;20:248-252.
3. Katz PO, Dalton CB, Richter JE, et al. Esophageal testing of patients with noncardiac chest pain or dysphagia. Results of three years' experience with 1161 patients. Ann Intern Med. 1987;106:593-597.
4. Glassman MS, Medow MS, Berezin S, et al. Spectrum of esophageal disorders in children with chest pain. Dig Dis Sci. 1992;37:663-666.
5. Lacy BE, Paquette L, Robertson D, et al. The Clinical Utility of Esophageal Manometry. Oral Presentation, American College of Gastroenterology Annual Meeting, October, 2005.
6. Ellis FG. The natural history of achalasia. Proc R Soc Med. 1960;53:663-666.
7. Csendes P, Csendes A, Cortes C, et al. Evolutive radiological changes of the esophagus in patients with achalasia who did not receive treatment. Surg Today. 2007;37:183-186.
8. Khatami SS, Khandwala F, Shay SS, et al. Does diffuse esophageal spasm progress to achalasia? A prospective cohort study. Dig Dis Sci. 2005;50:1605-1610.
9. Spencer HL, Smith L, Riley SA. A questionnaire study to assess long-term outcome in patients with abnormal esophageal manometry. Dysphagia. 2006;21:149-155.
10. Meshkinpour H, Haghighat P, Meshkinpour A. Quality of life among patients treated for achalasia. Dig Dis Sci. 1996;41:352-356.
11. Ben-Meir A, Urbach DR, Khajanchee YS, et al. Quality of life before and after laparoscopic Heller myotomy for achalasia. Am J Surg. 2001;181:471-474.
12. Urbach DR, Tomlinson GA, Harnish JL, et al. A measure of disease-specific health-related quality of life for achalasia. Am J Gastroenterol. 2005;100:1668-1676.
13. Panaccione R, Gregor JC, Reynolds RP, et al. Intrasphincteric botulinum toxin versus pneumatic dilation for achalasia: a cost minimization analysis. Gastrointest Endosc. 1999;50:492-498.
14. Kostic S, Johnson E, Kjellin A, et al. Health economic evaluation of therapeutic strategies in patients with idiopathic achalasia: results of a randomized trail comparing pneumatic dilation with laparoscopic cardiomyotomy. Surg Endosc. 2007;21:1184-1189.
15. Willis T. Pharmaceutice Rationalis Sive Diatribe do Medicamentorum Operationibus in Humano Corpore. London: Hagae Comitis; 1674.
16. Osgood H. A peculiar form of esophagismus. Boston Med Surg J. 1889;120:401-403.
17. Wong RKH, Maydonovitch CL. 1999. Achalasia. In: Castell DO, Richter JE, eds. The Esophagus. 4th ed. Philadelphia, PA: Lippincott Williams, & Wilkins; 2003:185-213.
18. Murray JA, Ledlow A, Launspach J, et al. The effects of recombinant human hemoglobin on esophageal motor functions in humans. Gastroenterology. 1995;109:1241-1248.
19. Champion JK, Delise N, Hunt T. Myenteric plexus in spastic motility disorders. J Gastrointest Surg. 2001;5:514-516.
20. Mayer EA, Tillisch K, Bradsei S. Modulation of the brain-gut axis as a therapeutic approach in gastrointestinal disease. Aliment Pharmacol Ther. 2006;24:919-933.
21. Friesen DL, Henderson RD, Hanna W. Ultrastructure of the esophageal muscle in achalasia and diffuse esophageal spasm. Am J Clin Pathol. 1983;79:319-325.
22. Dogan I, Puckett JL, Padda BS, et al. Prevalence of increased esophageal muscle thickness in patients with esophageal symptoms. Am J Gastroenterol. 2007;102:137-145.
23. Traube M, Dubovik S, Lange RC, et al. The role of nifedipine therapy in achalasia: results of a randomized, double-blind, placebo-controlled study. Am J Gastroenterol. 1989;84:1259-1262.
24. Triadafilopoulos G, Aaronson M, Sackel S, et al. Medical treatment of esophageal achalasia. Double-blind crossover study with oral nifedipine, verapamil, and placebo. Dig Dis Sci 1991;36:260-267.
25. Bortolotti M, Labo G. Clinical and manometric effects of nifedipine in patients with esophageal achalasia. Gastroenterology. 1981;80:39-44.
26. Coccia G, Bortolotti M, Michetti P, et al. Return of esophageal peristalsis after nifedipine therapy in patients with idiopathic esophageal achalasia. Am J Gastroenterol. 1992;87:1705-1708.
27. Gelfond M, Rozen P, Gilat T. Isosorbide dinitrate and nifedipine treatment of achalasia: a clinical manometric and radionuclide evaluation. Gastroenterology. 1982;83:963-969.
28. Wong RKH, Maydonovitch C, Garcia JE, et al. The effect of terbutaline sulfate, nitroglycerin, and aminophylline on lower esophageal sphincter pressure and radionuclide esophageal empting in patients with achalasia. J Clin Gastroenterol. 1987;9:386-389.
29. Levine ML, Moskowitz GW, Dorf BS, et al. Pneumatic dilation in patients with achalasia with modified Gruntzig dilator under direct endoscopic control: results after 5 years. Am J Gastroenterol. 1991;86:1581-1584.
30. Kadakia SC, Wong RK. Graded pneumatic dilation using Rigiflex achalasia dilators in patients with primary esophageal achalasia. Am J Gastroenterol. 1993;88:34-38.
31. Sanderson DR, Ellis FH, Olsen AM. Achalasia of the esophagus: results of therapy by dilation 1950-1967. Chest. 1970;58:116-121.
32. Eckardt VF, Aignherr C, Bernhard G. Predictors of outcome in patients with achalasia treated by pneumatic dilation. Gastroenterology. 1992;103:1732-1738.
33. West RL, Hirsch DP, Bartelsman JF, et al. Long term results of pneumatic dilation in achalasia followed for more than 5 years. Am J Gastroenterol. 2002;97:1346-1351.
34. Torquati A, Richards WO, Holzman MD, et al. Laparoscopic myotomy for achalasia: predictors of successful outcome after 200 cases. Ann Surg. 2006;243:587-591.
35. Ellis FH, Watkins E, Gibb SP, et al. Ten to 20 year clinic results after short esophagomyotomy without an antireflux procedure for esophageal achalasia. Eur J Cardiothorac Surg. 1992;6:86-89.
36. Jeansonne LO, White BC, Pilger KE, et al. Ten year follow-up of laparoscopic Heller myotomy for achalasia shows durability. Surg Endosc. 2007. [Epub ahead of print].
37. Csendes A, Brahghetto I, Henriquez A, et al. Late results of a prospective randomized study comparing forceful dilatation and oesophagomyotomy in patients with achalasia. Gut. 1989;30:299-304.
38. Richards WO, Torquati A, Holzman MD, et al. Heller myotomy vs. Heller myotomy with Dor fundoplication for achalasia: a prospective randomized double-blind clinical trial. Ann Surg. 2004;240:405-412.
39. Pasricha PJ, Rai R, Ravich WJ, et al. Botulinum toxin for achalasia: long term outcome and predictors of response. Gastroenterology. 1996;110:1410-1415.
40. Cuilliere C, Ducrotte P, Zerbib F, et al. Achalasia: outcome of patients treated with intrasphincteric injection of botulinum toxin. Gut. 1997;41:87-92.
41. Orlando RC, Bozymski EM. Clinical and manometric effects of nitroglycerin in diffuse esophageal spasm. N Engl J Med. 1973;289:23-25.
42. Swamy N. Esophageal spasm: clinical and manometric response to nitroglycerin and long acting nitrates. Gastroenterology. 1977;72:23-27.
43. Cattau EL, Castell DO, Johnson DA, et al. Diltiazem therapy for symptoms associated with nutcracker esophagus. Am J Gastroenterol. 1991;86:272-276.
44. Richter JE, Dalton CB, Bradley LA, et al. Oral nifedipine in the treatment of noncardiac chest pain in patients with nutcracker esophagus. Gastroenterology. 1987;93:21-28.
45. Davies HA, Lewis MJ, Rhodes J, et al. Trial of nifedipine for prevention of oesophageal spasm. Digestion. 1987;36:81-83.
46. Drenth JP, Bos LP, Engels LG. Efficacy of diltiazem in the treatment of diffuse oesophageal spasm. Aliment Pharmacol Ther. 1990;4:411-416.
47. Crozier RE, Glick ME, Gibb SP, et al. Acid-provoked esophageal spasm as a cause of non-cardiac chest pain. Am J Gastroenterol. 1991;86:1576-1580.
48. Clouse RE, Lustman PJ, Eckert TC, et al. Low dose trazadone for symptomatic patients with esophageal contraction abnormalities: a double-blind, placebo controlled trial. Gastroenterology. 1987;92:1027-1036.
49. Cannon RO, Quyyumi AA, Mincemoyer R, et al. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med. 1994;330:1411-1417.
50. Storr M, Allescher HD, Rosch T, et al. Treatment of symptomatic diffuse esophageal spasm by endoscopic injections of botulinum toxin: a prospective study with long term follow-up. Gastrointest Endosc. 2001;54:754-759.
51. Eherer AJ, Schwetz I, Hammer HF, et al. Effect of sildenafil on oesophageal motor function in healthy subjects and patients with oesophageal motor disorders. Gut. 2002;50:758-764.
52. Agrawal A, Tutuian R, Hila A, et al. Successful use of phosphodiesterase type 5 inhibitors to control symptomatic esophageal hypercontractility. Dig Dis Sci. 2005;50:2059-2062.
53. Triadafilopoulos G, Tsang HP, Segall GM. Hot water swallows improve symptoms and accelerate esophageal clearance in esophageal motility disorders. J Clin Gastroenterol. 1998;26:239-244.
54. Pimentel M, Bonorris GG, Chow EJ, et al. Peppermint oil improves the manometric findings in diffuse esophageal spasm. J Clin Gastroenterol. 2001;33:27-31.
55. Rao SC, Mudipalli RS, Remes-Troche JM, et al. Theophylline improves esophageal chest pain - a randomized, placebo-controlled trial. Am J Gastroenterol. 2007;102:930-938.
56. Rodriguez-Stanley S, Zubaidi S, Proskin HM, et al. Effect of tegaserod on esophageal pain threshold, regurgitation and symptom relief in patients with function heartburn and mechanical sensitivity. Clin Gastroenterol Hepatol. 2006;4:442-450.
57. Varia I, Logue E, O'Conner C, et al. Randomized trial of sertraline in patients with unexplained chest pain of noncardiac origin. Am Heart J. 2000;140:367-372.
58. Hong SJ, Ko BM, Jung IS, et al. Relevance of ineffective esophageal motility and hyperactive acid sensitization in patients with gastroesophageal reflux. J Clin Gastroenterol. 2007. [Epub ahead of print].
59. Agrawal A, Hila A, Tutuian R, et al. Bethanechol improves smooth muscle function in patients with severe ineffective esophageal motility. J Clin Gastroenterol. 2007;41:366-370.
60. Rajagopalan M, Kurian G, John J. Symptom relief with amitriptyline in the irritable bowel syndrome. J Gastroenterol Hepatol. 1998;13:738-741.
61. Drossman DA, Toner BB, Whitehead WE, et al. Cognitivebehavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology. 2003;125:19-31.
62. Julia V, Su X, Bueno L, et al. Role of neurokinin 3 receptors on responses to colorectal distention in the rat: electrophysiological and behavioral studies. Gastroenterology. 1999;116:1124-1131.
63. Okano S, Ikeura Y, Inatomi N. Effects of tachykinin NK1 receptor antagonists on the viscerosensory response caused by colorectal distension in rabbits. J Pharmacol Exp Ther. 2002;300:925-931.
64. Willert RP, Hobson AR, Delaney C. Neurokinin-1 receptor antagonism in a human model of visceral hypersensitivity. Aliment Pharmacol Ther. 2007;25:309-316.